The Executive and Professional’s Longevity Lab Panel - The 12 Blood Tests That Actually Change Decisions

Introduction: Why Your Annual Physical Is Not Enough

Your annual physical was designed to detect disease. It was never designed to detect aging.

Standard bloodwork—a basic metabolic panel, a lipid panel, a CBC—catches pathology that has already arrived. It tells you whether you have crossed a diagnostic threshold: diabetic or not, anemic or not, hypercholesterolemic or not. It was built for a reactive healthcare system that waits for disease and then treats it.

That is not the system we use at Bio Precision Aging. Where average is not the target, and where the goal is not merely the absence of disease but the optimization of every measurable system in your body, the standard panel is inadequate. It leaves the most consequential biomarkers unmeasured. It applies reference ranges derived from sick populations. And it misses metabolic dysfunction, inflammatory acceleration, and hormonal decline years—sometimes decades—before they produce symptoms.

In 2025, an international consortium of 60 aging researchers published a landmark consensus identifying validated biomarkers of biological aging—markers that predict not just disease, but the rate at which your body is aging at the cellular level. Simultaneously, the longevity medicine movement has demonstrated that comprehensive biomarker panels can detect dysfunction years before standard medicine raises a flag.

But more is not always better. The executive and high-performing professional does not need 250 biomarkers to make decisions. What you need is the right 12—the biomarkers where the gap between conventional reference ranges and longevity-optimized targets is widest, and where an actionable intervention exists today.

This article presents those 12 tests. For each, we define the conventional range, the longevity-optimized target, the clinical evidence behind the distinction, and the specific decisions the result should trigger. These are the tests that change what you do—not just what you know.

Quick Reference: The 12-Test Longevity Panel

The table below provides a summary of all 12 biomarkers, their conventional reference ranges, and the longevity-optimized targets that should drive clinical decision-making.

#	Biomarker	Category	Conventional	Longevity Target
1	Apolipoprotein B (ApoB)	Cardiovascular	< 130 mg/dL	< 80 mg/dL (< 70 if high risk)
2	Lipoprotein(a) [Lp(a)]	Cardiovascular / Genetic Risk	< 30 mg/dL (< 75 nmol/L)	< 30 mg/dL; lower is better
3	High-Sensitivity C-Reactive Protein (hs-CRP)	Inflammation	< 3.0 mg/L	< 1.0 mg/L (ideally < 0.5)
4	Hemoglobin A1c (HbA1c)	Metabolic / Glycemic Control	< 5.7% (non-diabetic)	4.8–5.2%
5	Fasting Insulin	Metabolic / Insulin Sensitivity	2.6–24.9 μIU/mL	< 5.0 μIU/mL (ideally 2–4)
6	Homocysteine	Methylation / Vascular Health	< 15 μmol/L	< 10 μmol/L (ideally 7–8)
7	Triglyceride/HDL-C Ratio (TG:HDL)	Metabolic / Insulin Resistance	Not routinely calculated	< 2.0 (ideally < 1.5)
8	Free Testosterone / Estradiol Panel	Hormonal / Vitality	Men: 5–21 pg/mL free T	Upper third of range; individualized
9	Thyroid Panel (TSH + Free T3 + Free T4)	Metabolic / Energy	TSH: 0.4–4.0 mIU/L	TSH: 1.0–2.0; Free T3 upper half
10	Vitamin D (25-OH Vitamin D)	Immune / Bone / Metabolic	30–100 ng/mL	50–80 ng/mL
11	Omega-3 Index	Inflammation / Cardiovascular / Cognitive	Not routinely tested	> 8% (ideally 8–12%)
12	HDL Function Panel with HDLfx pCAD Score	Cardiovascular / HDL Quality	Not routinely tested	pCAD Score < 71; pCEC in upper half of sex-specific range

The 12 Biomarkers: Evidence, Targets, and Decisions

1. Apolipoprotein B (ApoB)

Category: Cardiovascular

Conventional Range	Longevity-Optimized Target
< 130 mg/dL	< 80 mg/dL (< 70 if high risk)

Why It Matters for Longevity: ApoB directly counts every atherogenic lipoprotein particle in your bloodstream. Unlike LDL cholesterol, which measures cholesterol content, ApoB tells you how many particles are available to penetrate your arterial walls and initiate plaque formation. The FOURIER trial demonstrated that ApoB levels—not LDL-C—were the strongest predictors of cardiovascular benefit after treatment. Two patients with identical LDL cholesterol can have vastly different particle counts and vastly different risk. The European Atherosclerosis Society now identifies ApoB as the preferred marker for cardiovascular risk assessment, and the 2025 National Lipid Association Expert Consensus recommends stratified targets: below 90 mg/dL for intermediate risk, below 70 mg/dL for high risk, and below 60 mg/dL for very high-risk patients.

The Decision It Changes: An elevated ApoB triggers a conversation about statin or PCSK9 inhibitor therapy, dietary saturated fat reduction, and exercise prescription—even when your standard lipid panel looks reassuringly normal. It is the single most actionable cardiovascular biomarker for executives over 40.

2. Lipoprotein(a) [Lp(a)]

Category: Cardiovascular / Genetic Risk

Conventional Range	Longevity-Optimized Target
< 30 mg/dL (< 75 nmol/L)	< 30 mg/dL; lower is better

Why It Matters for Longevity: Lp(a) is a genetically determined particle approximately six times more atherogenic than ordinary LDL cholesterol. Levels are 80–90% heritable, stable from childhood, and unresponsive to diet or exercise. The 2025 international expert consensus identified Lp(a) among the top aging biomarkers, and the AHA’s 2026 dyslipidemia guidelines now recommend all adults measure Lp(a) at least once. Studies in long-lived populations show a striking absence of individuals with elevated Lp(a)—those with high levels appear to die before reaching advanced age.

The Decision It Changes: An elevated result permanently recalibrates your risk profile: more aggressive ApoB reduction targets, coronary calcium scoring, vascular imaging, and awareness of emerging siRNA therapies (lepodisiran showed 94% Lp(a) reduction in Phase II; pelacarsen outcomes expected 2026). This is a once-in-a-lifetime test.

3. High-Sensitivity C-Reactive Protein (hs-CRP)

Category: Inflammation

Conventional Range	Longevity-Optimized Target
< 3.0 mg/L	< 1.0 mg/L (ideally < 0.5)

Why It Matters for Longevity: Chronic low-grade inflammation is a fundamental driver of biological aging. The 2025 international aging biomarker consensus designated hs-CRP as a validated inflammation marker of aging. Levels above 3.0 mg/L significantly increase cardiovascular disease, cancer, and dementia risk. But the longevity-optimized target is below 1.0 mg/L—a threshold that predicts substantially lower all-cause mortality. For executives, chronic stress, sleep disruption, visceral adiposity, and pro-inflammatory diets converge to elevate this marker.

The Decision It Changes: An hs-CRP above 1.0 launches a root-cause investigation: sleep architecture assessment, visceral fat quantification, omega-3 index testing, dietary audit, and consideration of anti-inflammatory interventions. Below 1.0 validates that your strategy is working.

4. Hemoglobin A1c (HbA1c)

Category: Metabolic / Glycemic Control

Conventional Range	Longevity-Optimized Target
< 5.7% (non-diabetic)	4.8–5.2%

Why It Matters for Longevity: Standard medicine considers anything below 5.7% normal. Longevity medicine draws the line tighter. Centenarian studies consistently show HbA1c below 5.5% throughout life. An HbA1c of 5.6%—technically normal—already reflects glycemic dysregulation that accelerates arterial aging, advanced glycation end-product formation, and neurodegeneration. For professionals consuming frequent restaurant meals and experiencing chronic cortisol elevation, HbA1c drifts upward silently.

The Decision It Changes: An HbA1c above 5.2% prompts: continuous glucose monitoring trial, meal timing optimization, post-meal walking protocols, sleep quality assessment (poor sleep directly elevates fasting glucose), and resistance training prescription. A 5.4% in an otherwise healthy executive is not reassurance—it is a warning.

5. Fasting Insulin

Category: Metabolic / Insulin Sensitivity

Conventional Range	Longevity-Optimized Target
2.6–24.9 μIU/mL	< 5.0 μIU/mL (ideally 2–4)

Why It Matters for Longevity: Fasting insulin is the earliest detector of metabolic dysfunction—years before blood glucose or HbA1c begin to rise. Insulin resistance is the metabolic root of cardiovascular disease, certain cancers, cognitive decline, and accelerated aging. By the time fasting glucose is elevated, the pancreas has been compensating with excess insulin production for potentially a decade. In the HOMA-IR model, fasting insulin combined with fasting glucose calculates insulin resistance with high sensitivity.

The Decision It Changes: A fasting insulin above 5.0 μIU/mL, even with normal glucose, demands dietary restructuring: reduced refined carbohydrates, time-restricted eating evaluation, increased lean protein and fiber, and progressive resistance training. This biomarker catches metabolic aging before it becomes irreversible.

6. Homocysteine

Category: Methylation / Vascular Health

Conventional Range	Longevity-Optimized Target
< 15 μmol/L	< 10 μmol/L (ideally 7–8)

Why It Matters for Longevity: Elevated homocysteine damages the vascular endothelium, promotes thrombosis, accelerates cognitive decline, and reflects impaired methylation—one of the most critical biochemical processes in the body. It is directly linked to B-vitamin status (B12, folate, B6) and MTHFR gene variants that affect up to 40% of the population. Genetic testing frequently reveals the root cause behind persistently elevated levels.

The Decision It Changes: Homocysteine above 10 triggers methylation support: active B-vitamins (methylfolate, methylcobalamin, P5P), trimethylglycine supplementation, and MTHFR genetic testing if not yet performed. This is one of the most correctable biomarkers—levels respond within 8–12 weeks.

7. Triglyceride/HDL-C Ratio (TG:HDL)

Category: Metabolic / Insulin Resistance

Conventional Range	Longevity-Optimized Target
Not routinely calculated	< 2.0 (ideally < 1.5)

Why It Matters for Longevity: The triglyceride-to-HDL cholesterol ratio condenses two familiar lipid numbers into a compact snapshot of metabolic status that captures the push-pull between fat storage and lipid clearance. It is now recognized as one of the most powerful surrogate markers for insulin resistance—performing at least as strongly as HOMA-IR in predicting subclinical atherosclerosis and incident cardiovascular disease, while requiring no insulin measurement. A ratio above 3.0 in men or above 2.5 in women is highly predictive of metabolic syndrome. In prospective studies, TG:HDL ratio was more strongly associated with incident cardiovascular events than HOMA-IR alone. The European Society of Cardiology has noted its value as a clinical surrogate for insulin resistance. Because it derives from a standard lipid panel, it is the most cost-effective metabolic biomarker available—and one that most physicians never calculate.

The Decision It Changes: A TG:HDL ratio above 2.0 signals the need for aggressive lifestyle intervention: refined carbohydrate restriction, elimination of added sugars and seed oils, increased omega-3 intake, structured exercise (both aerobic and resistance), and evaluation of visceral adiposity. Track this ratio quarterly—it responds dynamically to behavioral changes and provides a real-time readout of whether your metabolic interventions are working. When combined with fasting insulin and HbA1c, the TG:HDL ratio completes the metabolic trifecta.

8. Free Testosterone / Estradiol Panel

Category: Hormonal / Vitality

Conventional Range	Longevity-Optimized Target
Men: 5–21 pg/mL free T	Upper third of range; individualized

Why It Matters for Longevity: Testosterone in men and estradiol in women are foundational to cardiovascular protection, bone density, cognitive sharpness, metabolic rate, and recovery capacity. Testosterone declines 1–2% per year after 30. In women, the menopausal transition creates dramatic shifts in cardiovascular risk and bone loss velocity. National guidance increasingly reflects what longevity clinicians have practiced: personalized, monitored hormone therapy improves cognitive stability, cardiovascular resilience, and overall vitality.

The Decision It Changes: Suboptimal levels trigger comprehensive evaluation: SHBG, prolactin, LH/FSH, and thyroid function. The decision tree includes lifestyle optimization first before considering TRT (men) or HRT timing and modality (women). This panel changes the conversation from “is this normal aging?” to “is this modifiable?”

9. Thyroid Panel (TSH + Free T3 + Free T4)

Category: Metabolic / Energy

Conventional Range	Longevity-Optimized Target
TSH: 0.4–4.0 mIU/L	TSH: 1.0–2.0; Free T3 upper half

Why It Matters for Longevity: Thyroid hormones regulate the metabolic rate of every cell. A TSH of 3.5—technically normal—often corresponds to subclinical hypothyroidism: fatigue, weight gain resistance, cognitive fog. Standard medicine tests only TSH; longevity medicine requires the complete triad. Free T3 is the active hormone at the cellular level, and its conversion from T4 can be impaired by stress, nutrient deficiencies (selenium, zinc, iron), inflammation, and gut dysfunction.

The Decision It Changes: TSH above 2.0 with Free T3 in the lower third prompts thyroid antibody screening (Hashimoto’s), selenium and zinc status, cortisol patterns, and ferritin levels. This panel determines whether your metabolic throttle is being pulled back at the cellular level.

10. Vitamin D (25-OH Vitamin D)

Category: Immune / Bone / Metabolic

Conventional Range	Longevity-Optimized Target
30–100 ng/mL	50–80 ng/mL

Why It Matters for Longevity: Vitamin D functions as a hormone influencing over 200 genes involved in immune regulation, inflammation, cancer surveillance, bone metabolism, and mood. An estimated 42% of American adults are deficient. Levels below 30 ng/mL are associated with increased all-cause mortality, while optimal longevity data clusters around 50–80 ng/mL. For those who work indoors and anyone over 50, supplementation is almost universally required.

The Decision It Changes: Levels below 50 ng/mL trigger D3 supplementation (4,000–8,000 IU daily depending on baseline), paired with K2 (MK-7) and magnesium for proper calcium metabolism. Retest at 12 weeks. One of the highest-impact, lowest-cost interventions in the panel.

11. Omega-3 Index

Category: Inflammation / Cardiovascular / Cognitive

Conventional Range	Longevity-Optimized Target
Not routinely tested	> 8% (ideally 8–12%)

Why It Matters for Longevity: The omega-3 index measures EPA and DHA as a percentage of total red blood cell fatty acids—a direct reflection of cell membrane composition and a powerful predictor of cardiovascular and cognitive outcomes. An index below 4% is associated with a 10-fold higher risk of sudden cardiac death compared to levels above 8%. Most Americans have an index between 4–5%—a range associated with accelerated biological aging.

The Decision It Changes: Below 8% demands dietary restructuring (wild-caught fatty fish 3–4x weekly) or EPA/DHA supplementation (2–4 grams daily). Retest at 16 weeks due to red blood cell turnover. One of the most responsive biomarkers to targeted supplementation.

12. HDL Function Panel with HDLfx pCAD Score

Category: Cardiovascular / HDL Quality

Conventional Range	Longevity-Optimized Target
Not routinely tested	pCAD Score < 71; pCEC in upper half of sex-specific range

Why It Matters for Longevity: For decades, medicine treated HDL cholesterol as a simple number—higher was better. But pharmacological trials that raised HDL-C levels failed to reduce cardiovascular events, revealing that HDL quantity and HDL function are fundamentally different questions. The HDL Function Panel, developed by Cleveland HeartLab (Quest Diagnostics), measures five apolipoproteins bound to ApoA-1 lipoprotein particles (ApoA1, ApoC1, ApoC2, ApoC3, ApoC4) using mass spectrometry and calculates two critical scores. The pCEC (predicted cholesterol efflux capacity) estimates how effectively your HDL particles remove cholesterol from arterial walls—the core protective mechanism of HDL. The pCAD Score integrates these apolipoprotein values into a risk classification for coronary atherosclerosis. In validation studies, a pCAD score above 71 identified coronary artery disease with 76% sensitivity and 75% specificity. Notably, ApoC-III carried on HDL particles was independently associated with cardiovascular mortality, suggesting that some HDL particles are not merely inactive but actively harmful. This panel answers the question that HDL-C alone cannot: are your HDL particles actually protecting you?

The Decision It Changes: A pCAD score above 71 triggers intensified cardiovascular risk management: tighter ApoB targets, consideration of coronary calcium scoring or CT angiography, evaluation of inflammatory and metabolic contributors to dysfunctional HDL (insulin resistance, chronic inflammation, oxidative stress), and aggressive lifestyle modification. For executives who have been told their HDL is “great” based solely on a high HDL-C number, this panel often reveals the uncomfortable truth that quantity and quality are not the same thing.

Building Your Longevity Lab Protocol

Testing Frequency

Baseline: All 12 tests, drawn fasting, with results interpreted against longevity-optimized targets—not conventional reference ranges. Lp(a) requires only a single lifetime measurement. The remaining 11 markers should be repeated at minimum annually, with quarterly monitoring recommended during active intervention periods.

Trending over time is more valuable than any single data point. A fasting insulin of 6.2 that was 8.4 twelve months ago tells a fundamentally different story than a fasting insulin of 6.2 that was 4.1 a year prior. Build the longitudinal record.

The Hierarchy of Action

Not all abnormal results carry equal urgency. Prioritize interventions in the following order:

First tier—immediate cardiovascular and metabolic risk: ApoB, Lp(a), fasting insulin, and HbA1c. These markers reflect the conditions most likely to cause a major adverse event in the next decade.

Second tier—inflammation and systemic aging: hs-CRP, homocysteine, HDL Function/pCAD Score, and omega-3 index. These reflect the pace of biological aging, the inflammatory milieu, and the functional quality of your lipoproteins.

Third tier—hormonal optimization and vitality: TG:HDL ratio, free testosterone/estradiol, thyroid panel, and vitamin D. These govern metabolic flexibility, energy, body composition, cognitive performance, and quality of life.

Where to Get Tested

The testing landscape has evolved dramatically. Comprehensive longevity panels are now available through direct-to-consumer platforms such as Function Health, Superpower, and SiPhox, as well as through longevity medicine practices like Cenegenics. For executives who prefer to work within their existing provider relationship, a printed requisition listing these 12 markers—with the longevity-optimized reference ranges included—gives any physician the information needed to order the panel through Quest Diagnostics or Labcorp.

What matters is not where you get tested. What matters is that the results are interpreted against the targets in this article—not against the population-derived reference ranges printed on the lab report.

Conclusion: From Data to Decades

The difference between a standard annual physical and a longevity lab panel is the difference between knowing you are not currently sick and knowing how fast you are aging. One is reactive. The other is predictive. One waits for disease. The other prevents it.

These 12 biomarkers represent the current evidence base for measurable, modifiable factors that predict healthspan and lifespan. Each one has been selected because it meets three criteria: the longevity-optimized target differs meaningfully from the conventional reference range, peer-reviewed evidence supports the tighter target, and an actionable intervention exists today.

At Bio Precision Aging, where average is not the target, we believe that the executives and professionals who will thrive in the decades ahead are those who treat their biology with the same rigor they apply to their portfolios, their businesses, and their strategic plans. The data is available. The interventions exist. The only question is whether you will measure what matters.

Your labs should not just tell you that you are alive. They should tell you how well you are aging—and what to do about it.

References

1. Walldius G, Jungner I, et al. High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events. Expert Review of Cardiovascular Therapy. 2025;23(8):521–566.

2. National Lipid Association Expert Consensus. Stratified apoB targets for cardiovascular risk management. Future Cardiology. 2025;21(12):987–989.

3. Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). New England Journal of Medicine. 2017;376(18):1713–1722.

4. Papadopoulos A, et al. Association of long-term exposure to elevated lipoprotein(a) levels with parental life span and mortality risk. JAMA Network Open. 2020;3(2):e200129.

5. Tsimikas S. Lipoprotein(a): a look back and a look ahead. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024;44:1027–1041.

6. Nissen SE, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a). JAMA. 2023;330(21):2075–2083.

7. Ridker PM, et al. Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women. New England Journal of Medicine. 2024;391(22):2087–2097.

8. Aging Biomarkers Consortium. International expert consensus on biomarkers of aging. Journals of Gerontology. 2025.

9. Dato S, Rose G, Crocco P, et al. Biomarkers of longevity and healthy aging. Mechanisms of Ageing and Development. 2022;200:111686.

10. Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573–591.

11. Harris WS, Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Preventive Medicine. 2004;39(1):212–220.

12. American Heart Association. 2026 Clinical Practice Guideline for the Management of Dyslipidemias. Circulation. 2026.

13. Parcha V, Bittner VA. Lipoprotein(a) in primary cardiovascular disease prevention is actionable today. American Heart Journal Plus. 2025;57:100581.

14. Cenegenics. 2025 in Review: The Longevity Trends That Redefine Healthspan. January 2026.

15. Natarajan P, Lyass A, Li Y, et al. Association of an HDL apolipoproteomic score with coronary atherosclerosis and cardiovascular death. Journal of the American College of Cardiology. 2019;73(17):2135–2145.

16. Jin Z, Collier TS, Dai DLY, et al. Development and validation of apolipoprotein AI-associated lipoprotein proteome panel for prediction of cholesterol efflux capacity and coronary artery disease. Clinical Chemistry. 2019;65(2):282–290.

17. Dullaart RPF, et al. Triglyceride/HDL cholesterol ratio and lipoprotein insulin resistance score: associations with subclinical atherosclerosis and incident cardiovascular disease. Clinical Chemistry and Laboratory Medicine. 2024;62(1).

18. Cordero A, et al. Usefulness of triglycerides-to-high-density lipoprotein cholesterol ratio for predicting the first coronary event in men. American Journal of Cardiology. 2009;104(10):1393–1397.

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Biomarker targets discussed represent emerging longevity medicine perspectives and may differ from current clinical guidelines. Always consult with a qualified healthcare provider before making changes to your health management strategy. Bio Precision Aging does not diagnose, treat, or prescribe.